“Global Asthma & COPD market set to grow to $47bn by 2024” says new Visiongain report

19 December 2018
Pharma

Visiongain has launched a new pharma report Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029: Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast.

The asthma and COPD market benefits from increasing prevalence of respiratory diseases, coupled with the high economic cost of those diseases. The industry will also have more biologics and synthetic anti-inflammatory agents for both asthma and COPD, as companies look to identify and offer treatments for multiple patient sub-groups.

The lead analyst of the report commented "Developments in treatment are expected to continue as new drugs and emerging technologies become more widely available. This may include personalised treatments for certain types of asthma not responding to the stepwise approach of the Global Initiative for Asthma (GINA) guidelines and treatments tailored to the specific composition of individual patient’s airway inflammation. Inhaler technology will continue to innovate with ‘intelligent’ delivery systems allowing more precise targeting of specific areas of the lungs becoming more common. In addition, inhaler-based health monitoring devices providing feedback of inhaler use to patients and healthcare professionals offer the promise of improved treatment adherence and health outcomes."

Leading companies featured in the report include Aerocrine (Circassia), ALK-Abello A/S, Amphastar Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Cipla, GlaxoSmithKline, Lallemand Pharma International, Merck, MundiPharma, Novartis and more.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Biobanking market set to grow to $4.2bn by 2024” says new Visiongain report

Biobanking infrastructure is improving at a global level with the establishment of large-scale national biobanks, population biobank projects, virtual biobanks and networking at national and international level.

23 May 2019

Read

“Global Urology Devices market set to grow to $9.3bn by 2023” says new Visiongain report

The market is driven by a number of factors such as aging population, technological advancements, and increasing awareness programs.

21 May 2019

Read

“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.

14 May 2019

Read

“Indian Pharmaceutical market set to grow to $71bn by 2024” says new Visiongain report

Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.

09 May 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1